Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is positioned to potentially disrupt the market and gain a significant market share with the positive results and unique mechanism of action of Roluperidone in the treatment of negative symptoms in schizophrenia. Furthermore, the company's dedicated focus on CNS diseases, with a strong pipeline including other promising drug candidates such as Seltorexant, indicates a strong growth potential. With promising clinical data and a successful asset, Minerva Neurosciences has the potential to deliver significant financial returns to investors in the long term.

Bears say

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. However, the company has faced challenges with its primary product candidate, roluperidone, failing to meet its primary endpoint in a Phase 3 trial and showing only numerical separation from placebo. Furthermore, there are concerns about the likelihood of positive symptom relapses and the potential for negative side effects with roluperidone as a monotherapy. These risks, combined with the limited market potential for a drug focused solely on treating negative symptoms in schizophrenia patients, lead to a negative outlook for Minerva Neurosciences's stock.

Minerva Neurosciences (NERV) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Buy based on their latest research and market trends.

According to 3 analysts, Minerva Neurosciences (NERV) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.